Intellectual Property
Our in-house Intellectual Property strategy is a cornerstone of our R&D-led innovation, enabling us to develop high-quality, differentiated biosimilars. Our R&D has consistently created intellectual wealth through an incisive intellectual property strategy that recognises the innovative potential of our products and processes.
With over 400 patents granted globally to our biosimilars, our IP framework is designed to navigate complex patent landscapes, support early market entry with a robust IP strategy across the globe, and make sure our lifesaving, life-changing therapies reach patients across the world on time.
By embedding IP deeply into our business strategy, we continue to unlock value, strengthen our competitive edge, and uphold our commitment to delivering innovative and inclusive healthcare solutions worldwide.
